Post Polycythemia Vera Myelofibrosis (PPV-MF) Market
Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market Size, Share, and Trends Analysis Report By Type (Durvalumab, Givinostat, Glasdegib, Idelalisib, IMG-7289, and Others), By Application (Hospital, Clinic, and Others), Forecast 2022-2028 Update Available - Forecast 2024-2030
The global post polycythemia vera myelofibrosis (PPV MF) market is expected to grow at a significant CAGR of 9.1% during the forecast period. The main factors that drive the PPV MF market are due to increasing incidence rates and a rise in awareness among the masses about PPV-MF diagnosis, increasing demand for newer treatment options with better efficacy and safety profile, and growing adoption of immunotherapy across various countries globally. Moreover, the growing adoption of the immunotherapy sector across the globe, and booming biotechnology across various countries will also boost the PPV MF market during the forecast period.
Impact of COVID-19 Pandemic on Post Polycythemia Vera Myelofibrosis (PPV MF) Market
The COVID-19 pandemic had impacted the global economy due to lockdown restrictions. The COVID-19 pandemic had caused enormous challenges in healthcare across the globe. Furthermore, the COVID-19 pandemic had impacted practically every phase of cancer care and research, from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research.
Segmental Outlook
The global post polycythemia vera myelofibrosis (PPV MF) Market is segmented based on type and application. By type, the market is segmented into durvalumab, givinostat, glasdegib, idelalisib, IMG-7289, and others. Based on the application, the market is sub-segmented into hospital, clinic, and others. Among these, Durvalumab is going to lead the post polycythemia vera myelofibrosis (PPV MF) market in the type segment. Furthermore, hospital is going to lead the post polycythemia vera myelofibrosis (PPV MF) market in the application segment.
Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market Share by Type, 2021 (%)
The Durvalumab is Holding a Prominent Share in the Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market
Durvalumab is holding the significant share in the market, mainly due to its’ interference with the activity of the human immune system by binding specific proteins on T cells and B cells, which are called immunoglobulins. It also blocks kidney inflammation caused due to high levels of uric acid in the bloodstream that cause gout pain or crystals formation in kidneys and other tissues such as muscles and joints, where it can lead to inflammation and arthritis pain. However, there is also a few side effects such as headache, diarrhea, nausea, upper respiratory tract infection (including sinusitis), increased coughs/colds symptoms which are impacting the growth of the market in the segment.
Regional Outlooks
Global post polycythemia vera myelofibrosis (PPV MF) market is further segmented in geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East and Africa, and Latin America). Asia-Pacific region is expected to witness significant growth opportunities for the market. Improving health care infrastructure is acting as the prime factor impacting the market in the region. Additionally, technology advancement and industry players are having large scope in this region especially in South Korea, China, and India for increasing their activity in the market.
Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market Growth, by region 2022-2028
North America region is estimated to Hold the Major Share in the Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market
North America is anticipated to hold a prominent share in the market mainly due to the high prevalence of hematological malignancies and stringent care protocol requirements. A statement was given by Leukemia and Lymphoma Society, around every 3 minutes, one person in the US is diagnosed with blood cancer. In addition, in US 1,806,590 new cancer cases were diagnosed in 2020. Thus, these are the few major reasons to drive the PPV MF market.
Market Players Outlook
The major companies serving the global post polycythemia vera myelofibrosis (PPV MF) market include Abbvie Inc., Celgene Corp., CTI BioPharma Corp., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., and Others. The growth of the market is considerably contributed by the market player for the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2022, AbbVie Inc. announced positive top-line results from U-EXCEL, a phase 3 induction study showing upadacitinib achieved both primary endpoints of clinical remission and endoscopic response at week. U-EXCEL is the second two phase 3 induction study to evaluate the safety and efficacy of upadacitinib in adults with moderate to serve Crohn’s disease who had an inadequate response or were intolerant to conventional or biologic therapy.
The Report Covers
- Market value data analysis of 2022 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global post polycythemia vera myelofibrosis (PPV MF) Market. Based on the availability of data, information related to the market, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market
• Recovery Scenario of Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Abbvie Inc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Celgene Corp.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. CTI BioPharma Corp.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. F. Hoffmann-La Roche Ltd.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Gilead Sciences Inc.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market by Type
4.1.1. Durvalumab
4.1.2. Givinostat
4.1.3. Glasdegib
4.1.4. Idelalisib
4.1.5. IMG-7289
4.1.6. Others
4.2. Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market by Application
4.2.1. Hospital
4.2.2. Clinic
4.2.3. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Incyte Corp.
6.2. Italfarmaco SpA
6.3. JW Pharmaceutical Corp.
6.4. Kartos Therapeutics Inc.
6.5. Karyopharm Therapeutics Inc.
6.6. Lynk Pharmaceutical Hangzhou Co. Ltd.
6.7. Medimmune LLC
6.8. MEI Pharma Inc.
6.9. Merck & Co Inc.
6.10. Novartis AG
6.11. NS Pharma Inc.
6.12. Promedior Inc.
6.13. Rhizen Pharmaceuticals AG
6.14. Samus Therapeutics Inc.
6.15. Sierra Oncology Inc.
6.16. Sino Biopharmaceutical Ltd.
6.17. Sun Pharma Advanced Research Co. Ltd.
6.18. Suzhou Zelgen Biopharmaceutical Co Ltd.
1. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL DURVALUMAB POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL GIVINOSTAT POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL GLASDEGIB POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL IDELALISIB POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL IMG-7289 POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL OTHERS POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
9. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET FOR HOSPITAL RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET FOR CLINIC RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET FOR OTHERS RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
14. NORTH AMERICAN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
15. NORTH AMERICAN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
16. EUROPEAN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. EUROPEAN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
18. EUROPEAN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
21. ASIA-PACIFIC POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
22. REST OF THE WORLD POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
23. REST OF THE WORLD POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
24. REST OF THE WORLD POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET, 2022-2028 (%)
4. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL DURVALUMAB POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL GIVINOSTAT POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL GLASDEGIB POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL IDELALISIB POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL IMG-7289 POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL OTHERS POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
12. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET FOR HOSPITAL, SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET FOR CLINIC, SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET FOR OTHERS, SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. US POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
17. CANADA POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
18. UK POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
19. FRANCE POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
20. GERMANY POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
21. ITALY POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
22. SPAIN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF EUROPE POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
24. INDIA POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
25. CHINA POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
26. JAPAN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
27. SOUTH KOREA POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF ASIA-PACIFIC POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
29. REST OF THE WORLD POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
